In the case of PARP-1 inhibitors, studies were historically focused on familial and sporadic breast and ovarian cancers with bi-allelic mutations in the HR repair genes BRCA1, BRCA2, or PALB2 (Hengel et al., 2016; Pommier et al., 2016). This evidence concerns the gene PARP1 and ovarian cancer.